At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
Dapagliflozin 10 mg per day for 3 months after initial catheter ablationdrug
Likely dose
Dapagliflozin 10 mg per day for 3 months after initial catheter ablationfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of DApagliflozin on REcurrence After Catheter Ablation for Atrial Fibrillation
In Brief
A clinical study evaluating Dapagliflozin 10 mg per day for 3 months after initial catheter ablation for Atrial Fibrillation. Completed, enrolled 200 participants across 1 site.
Detailed Summary
This is a single-center, parallel-group, randomized, open-label trial evaluating the effect of 3-month treatment with dapagliflozin 10mg once daily on the recurrence of atrial fibrillation after catheter ablation for atrial fibrillation in patients without diabetes, heart failure, or chronic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20252026
First PostedMay 2024
Enrollment StartJul 2024
Primary CompletionJul 2025
TodayJul 2026
First PostedMay 29, 2024
Enrollment StartJul 15, 2024
Primary CompletionJul 1, 2025
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 2.1 years ago
Interventions
Dapagliflozin 10 mg per day for 3 months after initial catheter ablationdrug
Dapagliflozin 10 mg per day for 3 months after initial catheter ablation